Praxis Precision Medicines, Inc.
PRAXPraxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders caused by neuronal excitation-inhibition imbalances.
Earnings
Next report
Aug 10, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders caused by neuronal excitation-inhibition imbalances. The company utilizes two proprietary platforms, Cerebrum and Solidus, to translate genetic insights into small molecule and antisense oligonucleotide (ASO) treatments. Their approach leverages translational tools and computational methodologies to target both rare genetic epilepsies and more prevalent neurological conditions.
A leading precision neuroscience company utilizing proprietary computational platforms to bridge the gap between genetic insights and clinical-stage CNS therapies.
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s market cap?
- Praxis Precision Medicines, Inc. (PRAX) has a market capitalization of $8.8B and trades on NASDAQ.
- Who are Praxis Precision Medicines, Inc.'s competitors?
- Praxis Precision Medicines, Inc.'s key competitors include Stoke Therapeutics, Jazz Pharmaceuticals, Polaryx Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Praxis Precision Medicines, Inc. partner with?
- Praxis Precision Medicines, Inc.'s notable partners include UCB Biopharma SRL, Ionis Pharmaceuticals, Sage Therapeutics, and others.
- Where is Praxis Precision Medicines, Inc. headquartered?
- Praxis Precision Medicines, Inc. is headquartered in United States of America and employs approximately 82 people. It has been publicly traded since 2020.